Molecular Biometrics has changed the name of its first, groundbreaking product for embryo viability assessment from ViaTest™ to ViaMetrics™. We look forward to providing additional updates as we move toward product launch.
Molecular Biometrics, Inc., is applying novel metabolomic technologies to develop accurate, non-invasive methodologies for evaluating normal biologic function in health and disease, and for drug discovery and development. The company’s proprietary technology is being applied in reproductive health, neurodegenerative disease (Alzheimer’s disease and Parkinson’s disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism.
Click here for Company information